Elevated HbA1c Usually Leads to Prompt Tx Start, Intensification
Within 6 months of elevated HbA1c, rate of initiation 63%, rate of intensification 82%.
(HealthDay News) -- Most patients are newly initiated on antidiabetic therapy or have antidiabetic therapy intensified within 6 months of hemoglobin A1c (HbA1c) elevation, according to a study published online in Diabetes Care.
Lauren G. Gilstrap, MD, from Harvard Medical School in Boston, and colleagues used data from 2008 to 2015 commercial claims linked with laboratory and pharmacy data to create an initiation cohort with no prior antidiabetic drug use (9799 patients) and an intensification cohort of patients who were on a stable dose of one noninsulin diabetic drug (10,941 patients); both cohorts had HbA1c levels ≥8%.
The researchers found that 63% of patients in the initiation cohort received an antidiabetic drug within six months of the elevated HbA1c test; 82% of the intensification cohort had their existing antidiabetic therapy intensified within 6 months of the elevated HbA1c test. Higher rates of initiation and intensification were seen in association with higher HbA1c levels, lower generic drug copayments, and more frequent office visits. Correlations with intensification were seen for better patient adherence before elevated HbA1c level, existing therapy with a second-generation antidiabetic drug, and lower doses of existing therapy. Patient factors explained 7.96 and 7.35% of the variation in initiation and intensification, respectively.
"Additional work to examine whether other patient, physician, or practice factors explain more of the variation in antidiabetic treatment patterns should be considered," the authors write.
The study was partially funded by Merck Sharpe & Dohme and the Pharmaceutical Research and Manufacturers of America.
Gilstrap LG, Mehrotra A, Bai B, et al. Original Research. National Rates of Initiation and Intensification of Antidiabetic Therapy Among Patients With Commercial Insurance. Diab Care 2018 May; dc172585. DOI: 10.2337/dc17-2585